Arcus Biosciences grants RSUs and options to director
Arcus Biosciences director David L. Lacey received new equity awards on common stock.
Rhea-AI Filing Summary
Arcus Biosciences director David L. Lacey received new equity awards on common stock. He was granted 5,700 restricted stock units, increasing his direct common stock holdings to 76,652 shares after the award.
He also received a stock option for 16,900 shares with an exercise price of $23.30 per share, expiring on June 10, 2036. Both the RSUs and the option vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and each will become fully vested if the company is subject to a change in control.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,600 shares
Grant/Award
2 txns
Insider
Lacey David L.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 16,900 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 5,700 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 16,900 contracts (Direct);
Common Stock — 76,652 shares (Direct)
Footnotes (2)
- F1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
- F2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Key Figures
RSUs granted: 5,700 units
Options granted: 16,900 shares
Option exercise price: $23.30 per share
+2 more
5 metrics
RSUs granted
5,700 units
Restricted stock units granted to director on June 11, 2026
Options granted
16,900 shares
Stock option award to buy common stock
Option exercise price
$23.30 per share
Strike price for 16,900-share option grant
Option expiration
June 10, 2036
Expiration date of stock option grant
Shares held after grant
76,652 shares
Director’s direct common stock holdings following RSU grant
Key Terms
restricted stock units, change in control, stock option, annual meeting of stockholders
4 terms
restricted stock units financial
"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"The RSUs will become fully vested in the event the Company is subject to a change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
stock option financial
"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
annual meeting of stockholders financial
"vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Arcus Biosciences (RCUS) grant to David L. Lacey?
Arcus Biosciences granted David L. Lacey 5,700 restricted stock units and a stock option for 16,900 shares of common stock. These awards are compensation-related grants, not open-market purchases, and were reported as acquisitions on a Form 4 filing.
What is the vesting schedule for David L. Lacey’s new RCUS RSUs and options?
Both the 5,700 RSUs and the 16,900-share stock option vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders. This means vesting timing depends on when the company next holds its annual shareholder meeting.
At what price can David L. Lacey exercise his new Arcus Biosciences stock options?
The new stock option granted to David L. Lacey has an exercise price of $23.30 per share for 16,900 shares of common stock. The option expires on June 10, 2036, giving a long window to exercise after vesting conditions are met.
What happens to David L. Lacey’s RCUS RSUs and options if there is a change in control?
If Arcus Biosciences is subject to a change in control, both the 5,700 RSUs and the 16,900-share stock option become fully vested. This accelerates vesting regardless of the original schedule tied to June 11, 2027 or the next annual meeting.
Are David L. Lacey’s recent RCUS transactions open-market buys or compensation grants?
The transactions are compensation grants, not open-market buys. The Form 4 lists them under code “A” as grant, award, or other acquisition, covering 5,700 restricted stock units and a 16,900-share stock option award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
